#Singapore #Louis Widmer #Hyphens Pharma #Cerapro MED

Hyphens Pharma Secures European License for Cerapro® MED

In a significant move for skin health, Hyphens Pharma International Limited has announced that its innovative product, Cerapro® MED Skin Barrier Cream, has received licensing approval for commercial distribution across six European countries, including Switzerland, Austria, the Netherlands, Belgium, Luxembourg, and Liechtenstein. This licensing agreement has been established with Louis Widmer SA, a reputable Swiss company known for its dermatological products, via a license and supply agreement.

Cerapro® MED is specifically designed to address the needs of individuals suffering from atopic dermatitis, a common form of eczema affecting millions globally. The cream features a patented formula that effectively lowers skin pH, helping to restore the skin barrier, a crucial aspect in treating this condition. The product has been approved as a medical device under the European Medical Device Regulation (CE marking), marking it as a valid treatment option for eczema patients.

Partnership Insights

According to the licensing agreement, Hyphens Pharma will receive an upfront payment alongside regular royalties from sales of the product. The collaboration aims to leverage the dermatological expertise of Louis Widmer for promoting Cerapro® MED to dermatologists and pediatricians within the designated markets. Mr. Lim See Wah, CEO of Hyphens Pharma, emphasized the significance of this partnership, highlighting the companies’ shared commitment to innovation and patient care.

"This important partnership underscores our commitment to innovation and patient care," said Mr. Lim. "By leveraging Louis Widmer’s strong presence and expertise in dermatology, we hope to bring Cerapro® to European patients while exploring new growth opportunities."

The Science Behind Cerapro® MED

Atopic dermatitis is characterized by elevated skin pH and disruption of skin barrier function. Cerapro® MED addresses these issues through its unique formulation, which not only lowers skin pH but also enhances the skin’s innate antimicrobial defense system, promoting healthier skin function.

The effectiveness of Cerapro® MED as a treatment for atopic dermatitis is poised to provide much-needed relief for patients, responding to a critical need within the dermatological community.

Louis Widmer's Role in the European Market

Louis Widmer, established in 1960, is famed for its commitment to quality skincare products. The firm has a longstanding reputation for providing effective solutions for dry and atopic skin conditions. Ms. Annemarie Widmer, CEO of Louis Widmer, expressed enthusiasm about the partnership, stating that Cerapro® will serve as a flagship product within their Remederm line, which is already a leader in Europe for treating dry and atopic skin.

"We are thrilled to partner with Hyphens Pharma to launch Cerapro® in our markets, providing patients with a clinically proven solution for atopic dermatitis," said Ms. Widmer, adding that the product fits seamlessly into their existing portfolio that focuses on quality care for sensitive skin types.

A Vision for Accessible Healthcare

Hyphens Pharma champions the idea that everyone should have access to products that enhance their quality of life. The group's base in Singapore serves as a springboard for operations extending throughout Southeast Asia, where they distribute specialty pharmaceuticals and develop exclusive dermatological products. Their expansive ecosystem includes digital health solutions, making prescription medications more accessible for healthcare providers and patients alike.

As the partnership unfolds, both Hyphens Pharma and Louis Widmer are dedicated to enhancing patient outcomes through innovative skin care solutions. With Cerapro® MED on the brink of hitting the European markets in 2026, the collaboration marks a positive step towards better management of atopic dermatitis for patients across Europe. This venture not only signifies a business relationship but a shared vision aimed at improving skin health on a broader scale.